A Multi-Center, Non-Interventional Study to Evaluate Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab (ACROSS)
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ACROSS
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 01 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 01 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.